Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 12, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Updates in Childhood Acute Lymphoblastic Leukemia.

Sara Zarnegar-Lumley1, Jennifer L McNeer2

  • 1Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

Hematology/Oncology Clinics of North America
|June 10, 2026
PubMed
Summary

Recent studies reveal distinct acute lymphoblastic leukemia (ALL) subgroups driven by specific genomic changes. Targeted therapies and immunotherapies are now being developed for relapsed/refractory pediatric ALL based on these findings.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncofertility in Pediatric and Adolescent Patients: Current Practice and Future Directions.

Hematology/oncology clinics of North America·2026
Same author

Advances in Pediatric Oncology: Enhancements in Risk Stratification, Targeted Therapeutics, and Cancer Survivorship Care.

Hematology/oncology clinics of North America·2026
Same author

Blinatumomab Utilization in Pediatric B-Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West.

Pediatric blood & cancer·2026
Same author

American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.

Blood advances·2026
Same author

Surgical Fertility Preservation Can Be Safely Performed Without Delaying Treatment for Children With Severe Aplastic Anemia.

Pediatric blood & cancer·2025
Same author

Germline Variant Burden Warrants Universal Genetic Testing in Pediatric Myeloid Leukemia.

medRxiv : the preprint server for health sciences·2025

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • Molecular studies have identified specific subgroups of acute lymphoblastic leukemia (ALL) driven by genomic aberrations.
  • The development of immunotherapy has significantly impacted cancer treatment, with effective agents now available for B-cell ALL (B-ALL).

Purpose of the Study:

  • To highlight the progress in understanding molecular drivers of pediatric ALL.
  • To discuss the development of targeted agents and immunotherapies for relapsed/refractory pediatric ALL (R/R-ALL).

Main Methods:

  • Review of recent molecular studies identifying genomic aberrations in ALL subgroups.
  • Analysis of the advent and application of immunotherapy in B-ALL treatment.
  • Identification of potential therapeutic targets on leukemic blasts.
Keywords:
ImmunotherapyPediatric acute leukemiaPh-like ALLTargeted therapy

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Main Results:

  • Genomic aberrations, not just chromosomal rearrangements or aneuploidy, define certain ALL subgroups.
  • Effective immunotherapeutic agents have been developed for B-ALL.
  • Targeted agents and immunotherapies are emerging for pediatric R/R-ALL.

Conclusions:

  • Understanding molecular drivers is crucial for advancing pediatric ALL treatment.
  • Targeted therapies and immunotherapies represent a promising frontier for R/R-ALL.